CSTE Legionnaires' Disease Surveillance Workgroup

The purpose of this workgroup is to inform and improve practices related to Legionnaires’ disease surveillance and response in local, state, tribal, and territorial settings.

Document 19-ID-04_Legionellosis_NationalOfficeReviewed_Revised_4_17_2019_Re-submission.pdf (561 KB)

Download ↓

Position statement resubmitted to CSTE.

Comments & Events

Paul G. posted this on · Download ↓
Paul G. added a new version on · Download ↓
Kathleen Ross
I was going to add this suggestion to the tracking form but was having difficulty trying copy and paste it. Hope it's okay here. I highlighted the main changes in yellow. 

Probable healthcare-associated: 
  • A case with ≥ 10 days (1) of continuous inpatient stay at one or more healthcare facilities (2,3) during the 14 days before onset of symptoms.
Possible healthcare-associated: 
  • A case with < 10 days of continuous inpatient stay at one or more healthcare facilities during the 14 days before onset of symptoms; OR
  • A case with any non-inpatient exposure (4) at any healthcare facility during the 14 days before onset of symptoms.

  1. The majority of Legionnaires’ disease cases have illness onset within 10 days of exposure; for investigation purposes, the goal is to capture the most likely exposure source.
  2. Public health officials should consider a patient who spent the entire 10 days before date of symptom onset in multiple healthcare facilities (e.g., a patient who is discharged directly from an acute care hospital to a long-term care facility) as a probable healthcare-associated case for surveillance purposes. The distinction between the facilities would be important for investigation purposes.
  3. Examples of healthcare facilities include acute care facilities, long term acute care facilities, skilled nursing facilities, and clinics
  4. Examples of non-inpatient exposures include outpatient visits, visitors, employees, and volunteers. 

Paul G. added a new version on · Download ↓
Paul G. added a new version on · Download ↓
Vivian H. added a new version on · Download ↓
Seema Jain
Hi all - I just reviewed the latest version of the PS.  Very nice job and so much work- kudos!  My only one question is do we want to be more specific when we say respiratory secretions - is this meant to be lower respiratory or upper or both or sputum?  When we have reviewed earlier, we had found that PCR is only validated for LRT specimens and not NP/OP but I am wondering if we need to be more specific about what is meant by specimen type on this document?  Thanks to everyone for all their hard work on this.  Best, Seema
Vivian H. added a new version on · Download ↓
Paul G. added a new version on · Download ↓